Enhanced hepatoprotective effects of empagliflozin and vitamin D dual therapy against metabolic dysfunction-associated steatohepatitis in mice by boosted modulation of metabolic, oxidative stress, and inflammatory pathways.
Although single treatment with sodium-glucose cotransporter-2 inhibitors (SGLT2i) or vitamin D (VD) inhibited metabolic dysfunction-associated steatohepatitis (MASH) development in diabetic patients, their combination has not...
Read More